Shailender Bhatia, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Agenus
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    03/01/2025
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Bristol Meyers Squibb
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    03/01/2025
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Regeneron (fka Checkmate Pharmaceuticals)
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    03/01/2025
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    EMD Serono
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    03/01/2025
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Incyte
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    03/01/2025
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Merck
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    03/01/2025
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Trisalus Life Sciences
    Topic:
    Research funding
    Date added:
    03/09/2023
    Date updated:
    03/01/2025
    Relationship end date:
    03/10/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    Advisory board
    Date added:
    02/13/2024
    Date updated:
    03/01/2025
    Relationship end date:
    07/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Incyte
    Topic:
    Consultant
    Date added:
    02/13/2024
    Date updated:
    03/01/2025
    Relationship end date:
    03/15/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Replimune
    Date added:
    02/28/2025
    Date updated:
    03/01/2025

Pages

Return to Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery